



**Reducing Risks,  
Enhancing  
Heart Health**

**In Medical management of ACS patients / Undergoing PCI**



Rx

**MLTica<sup>®</sup>**

**Ticagrelor 90 mg Tablets**





## Background

Cardiovascular diseases remain the leading cause of death worldwide, with India facing a significantly higher burden compared to global averages. Patients diagnosed with acute coronary syndrome (ACS) are at an increased risk of thrombotic events, such as strokes, making effective antiplatelet therapy essential. According to the ACC guidelines, switching to ticagrelor monotherapy after completing a 3-month dual antiplatelet therapy (DAPT) regimen in ACS patients undergoing PCI reduces major bleeding risks without increasing ischemic events when compared to continuing ticagrelor and aspirin. Studies confirm ticagrelor's superior efficacy over older agents in reducing cardiovascular events, including strokes, with its rapid onset of action providing notable clinical benefits and improving patient adherence.

## Product description

MLTica contains Ticagrelor 90 mg Tablets

## Indication

MLTica (Ticagrelor) is indicated In medical management of ACS patients/Undergoing PCI

## Mechanism of Action

**MLTica** (Ticagrelor) functions by selectively inhibiting the P2Y<sub>12</sub> receptor on platelets, which is activated by ADP (adenosine diphosphate). This activation typically leads to platelet aggregation and clot formation. By blocking this receptor, MLTica prevents platelet clumping, reducing the likelihood of blood clot formation in the arteries, which improves blood flow in patients with cardiovascular conditions like ACS.

## Dosage & Administration

- **For ACS Management:**

Initiate treatment with a 180 mg loading dose orally.

- **After the Initial Dose:**

Administer 90 mg twice daily for the first year following an ACS event.

After one year, reduce the dose to 60 mg twice daily.

- **Contraindication:**

Do not administer MLTica with other oral platelet inhibitors.

\* PCI-Percutaneous Coronary Intervention



**Corp. & Regd. Office:**

1009-1010, Chiranjiv Tower, 43, Nehru Place, New Delhi - 110019 Tel.: 011-47589500-51 (50 lines)

E-mail: [info@medicamenlifesciences.com](mailto:info@medicamenlifesciences.com) | Web: [www.medicamen.com/lifesciences](http://www.medicamen.com/lifesciences)

I am: \_\_\_\_\_

Call me on: \_\_\_\_\_

Mail me at: \_\_\_\_\_